IL144764A0 - Eplerenone crystalline form exhibiting enhanced dissolution rate - Google Patents

Eplerenone crystalline form exhibiting enhanced dissolution rate

Info

Publication number
IL144764A0
IL144764A0 IL14476400A IL14476400A IL144764A0 IL 144764 A0 IL144764 A0 IL 144764A0 IL 14476400 A IL14476400 A IL 14476400A IL 14476400 A IL14476400 A IL 14476400A IL 144764 A0 IL144764 A0 IL 144764A0
Authority
IL
Israel
Prior art keywords
crystalline form
dissolution rate
exhibiting enhanced
enhanced dissolution
form exhibiting
Prior art date
Application number
IL14476400A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL144764A0 publication Critical patent/IL144764A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14476400A 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate IL144764A0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16955699P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16969099P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
PCT/US2000/032416 WO2001042272A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Publications (1)

Publication Number Publication Date
IL144764A0 true IL144764A0 (en) 2002-06-30

Family

ID=27558585

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14476400A IL144764A0 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate
IL144764A IL144764A (en) 1999-12-08 2001-08-06 A crystalline form of applernon that reveals an increased rate of decay
IL176511A IL176511A (en) 1999-12-08 2006-06-22 A crystalline form of applernon that reveals an increased rate of decay

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL144764A IL144764A (en) 1999-12-08 2001-08-06 A crystalline form of applernon that reveals an increased rate of decay
IL176511A IL176511A (en) 1999-12-08 2006-06-22 A crystalline form of applernon that reveals an increased rate of decay

Country Status (17)

Country Link
EP (1) EP1177204A2 (https=)
JP (1) JP2003516414A (https=)
KR (1) KR100607923B1 (https=)
CN (2) CN1152886C (https=)
AU (1) AU784946B2 (https=)
BR (1) BR0008057A (https=)
CA (1) CA2362669A1 (https=)
CO (1) CO5280211A1 (https=)
EA (1) EA007934B1 (https=)
HU (1) HUP0203032A3 (https=)
IL (3) IL144764A0 (https=)
MX (1) MXPA01008056A (https=)
MY (1) MY131878A (https=)
NO (1) NO20013856L (https=)
NZ (2) NZ530028A (https=)
PE (1) PE20010917A1 (https=)
WO (1) WO2001042272A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072797A1 (en) * 2002-03-20 2004-04-15 Pornanong Aramwit Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции
CN120754115A (zh) * 2025-05-23 2025-10-10 远大医药(中国)有限公司 一种含依普利酮组合物及其药物制剂、制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
PT944644E (pt) * 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
WO2001042272A3 (en) 2001-11-29
NZ530028A (en) 2005-08-26
WO2001042272A9 (en) 2002-12-12
HUP0203032A2 (hu) 2002-12-28
NO20013856D0 (no) 2001-08-08
MXPA01008056A (es) 2003-07-21
AU2049201A (en) 2001-06-18
CN1377365A (zh) 2002-10-30
IL144764A (en) 2007-08-19
CN1152886C (zh) 2004-06-09
KR100607923B1 (ko) 2006-08-04
HK1050536A1 (en) 2003-06-27
CN1557833A (zh) 2004-12-29
EP1177204A2 (en) 2002-02-06
AU784946B2 (en) 2006-08-03
CA2362669A1 (en) 2001-06-14
KR20010112261A (ko) 2001-12-20
NO20013856L (no) 2001-10-08
HUP0203032A3 (en) 2003-04-28
PE20010917A1 (es) 2001-09-10
CO5280211A1 (es) 2003-05-30
MY131878A (en) 2007-09-28
EA200100871A1 (ru) 2002-04-25
NZ513961A (en) 2004-02-27
BR0008057A (pt) 2002-04-23
JP2003516414A (ja) 2003-05-13
IL176511A (en) 2007-08-19
EA007934B1 (ru) 2007-02-27
WO2001042272A2 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
AU142262S (en) Towel
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
EP1166786A4 (en) MEDICAL COMPOSITIONS
GB0016698D0 (en) Tie
HUP0202255A3 (en) Crystalline 1-methylcarbapenem compounds and pharmaceutical compositions containing them
IL144764A0 (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
CA90059S (en) Towel
AU142964S (en) Clock
IL144757A0 (en) Eplerenone crystalline form
IL151551A0 (en) Crystalline pharmaceutical
IL153226A0 (en) Crystalline therapeutic agent
CA86217S (en) Towel
ZA200107145B (en) Eplerenone crystalline form exhibiting enhanced dissolution rate.
CA86214S (en) Towel
CA86215S (en) Towel
HU0003380D0 (en) Reversible plough
SI1305314T1 (en) Crystalline therapeutic agent
CA89270S (en) Tie
CA86216S (en) Towel
TW414329U (en) Clock structure for displaying multiple times
GB9925372D0 (en) Tie
GB0001176D0 (en) Tie
HU0002045D0 (en) Unipolar crystal
GB9906607D0 (en) Oral composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed